Fusion Pharmaceuticals adds Dr Pablo Cagnoni to its Board as Independent Director

– CANADA, Hamilton / USA, MA –  Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, today announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors as an independent director. It adds an oncology drug development leader as the Company advances its clinical programs and expands its pipeline.

“As an oncologist and prominent industry executive, Pablo brings to the Fusion Board deep and relevant experience developing breakthrough cancer therapies,” said Damian Lamb, Chairman.

“With Fusion’s completion of a Series B financing and lead program FPI-1434 entering the clinic, this has been a pivotal year setting the Company on a rapid growth trajectory. Pablo will provide valuable strategic guidance as we advance our clinical programs and expand our pipeline,” he added.

About Dr Pablo Cagnoni

Over the course of Dr. Cagnoni’s career, he has played a key role in the development, approval and commercialization of more than 20 important treatments. He currently serves as chief executive officer of Rubius Therapeutics, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines. He previously was president and CEO of Tizona Pharmaceuticals, a privately-held biotech company focused on developing next-generation immunotherapies for the treatment of cancer. Prior to Tizona, he served as president of Onyx Pharmaceuticals, where he had global strategic oversight of the business from early product development to commercialization of the Onyx portfolio. Previously, he was senior vice president and global head of clinical development at Novartis Oncology, where he was responsible for the clinical development of all oncology programs. He has also served in senior management roles at Allos Therapeutics and OSI Pharmaceuticals. Dr. Cagnoni was previously an assistant professor of medicine and assistant director of the pharmacology laboratory at the University of Colorado Bone Marrow Transplant Program.

“Fusion has established itself as a leader in the field of targeted alpha therapy creating next-generation cancer treatments,” said Dr. Cagnoni. “I believe a significant opportunity exists to leverage Fusion’s Fast-Clear™ Linker to advance a pipeline of innovative oncology drugs. I’m excited to join the Board and help guide Fusion’s strategic plan and growth.”

Dr. Cagnoni received his medical degree from the University of Buenos Aires School of Medicine. He completed fellowships in hematology and oncology at the Mount Sinai Medical Center, and in stem cell transplantation at the University of Colorado Health Sciences Center.

About Fusion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer. Using its proprietary Fast-Clear Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments. In preclinical studies, the Company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact on healthy tissue. Fusion’s lead program, FPI-1434, is currently in a Phase 1 trial. The Company completed an oversubscribed $125M Series B financing that will be used to advance FPI-1434 and initiate preclinical and clinical development on multiple new agents.

With a proprietary discovery platform, Fusion is actively in-licensing targeting molecules and forming strategic partnerships to expand its pipeline of cancer therapies.

For more information: https://fusionpharma.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.